openPR Logo
Press release

Pancreatic Cancer Market to Progress at a CAGR of 7.3 % by 2032 | DelveInsight

08-30-2022 02:27 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Pancreatic Cancer Market

Pancreatic Cancer Market

DelveInsight's Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

The pancreatic cancer market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medicine development.

Key takeaways from Pancreatic Cancer Market Report
• As per DelveInsight analysis, the pancreatic cancer market size in the 7MM was approximately USD 1,649 million in 2021.
• As per the estimates, the total incident cases of pancreatic cancer were approx 175K in the 7MM in 2021.
• Leading pancreatic cancer companies such as AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicùm Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others are developing novel pancreatic cancer drugs that can be available in the pancreatic cancer market in the upcoming years.
• The pancreatic cancer therapies in the pipeline include Motixafortide, Mitazalimab, BPX-601, Tedopi (OSE2101), AZD5305, Elraglusib (9 ING 41), NT-I7 (Efineptakin Alfa), Olaptesed pegol (NOX-A12), siG12D LODER, Sotorasib (LUMAKRAS/AMG 510), NGM120, Zenocutuzumab (Zeno, MCLA-128), Adagrasib (MRTX849), RX-3117, Anktiva (N-803), BPM31510 (ubidecarenone), Zejula (niraparib), Glufosfamide, LOAd703 (delolimogene mupadenorepvec), Pamrevlumab, GVAX Pancreatic Tumor Vaccine, and others.
• The pancreatic cancer market is expected to grow due to factors like an increase in the patient pool and the expected launch of novel emerging therapies.

Download Sample Report- https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Cancer Overview
Pancreatic cancer develops in the tissues of the pancreas, an organ in the abdomen located behind the bottom portion of the stomach. The pancreas produces hormones that assist control blood sugar and release enzymes that promote digestion. Pancreatic cancer is a disorder in which malignant (cancer) cells originate in pancreatic tissues. The pancreas can grow in various ways, including malignant and noncancerous tumors. However, the exact pancreatic cancer causes are unknown. The average life expectancy of pancreatic cancer for individuals who are diagnosed before the tumor develops or spreads is 3 to 3.5 years.

Pancreatic Cancer Symptoms
Pancreatic cancer symptoms may include jaundice, dark urine, weight loss, and loss of appetite, weariness, and others. The pancreatic cancer diagnosis is difficult as the symptoms are frequently confused with those of other disorders, such as irritable bowel syndrome. Pancreatic cancer treatment options are determined by the degree of cancer. Options may include surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these.

Pancreatic Cancer Epidemiology Segmentation in the 7MM
• Total Pancreatic cancer Incident Cases
• Pancreatic cancer Molecular Alteration-specific Incident Cases
• Pancreatic cancer Stage-specific Incident Cases

Pancreatic Cancer Treatment Market
Surgical treatment is preferred for patients whose disease has been identified as localized or regional. Aside from surgery, chemotherapy is the most popular pharmaceutical pancreatic cancer treatment option. It is preferred for pancreatic cancer patients in all situations. Gemcitabine-based chemotherapeutic regimens are favored over 5-FU-based and other regimens in first-line therapy due to fewer side effects associated with gemcitabine compared to 5-FU-based treatment choices.
Gemcitabine + nab-paclitaxel can be used as second-line therapy for individuals who meet certain criteria and have had first-line FOLFIRINOX. In the second-line scenario, monotherapy with GEM or 5-FU is possible for patients with a somewhat low-performance status (ECOG 2), those with medical comorbidities, or elderly patients.

Discover more information of the report offering- https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Cancer Pipeline Therapies and Key Companies
• Motixafortide (BL-8040): BioLineRx/Merck Sharp & Dohme
• Mitazalimab (ADC-1013): Alligator Bioscience
• BPX-601: Bellicùm Pharmaceuticals
• Tedopi (OSE2101): OSE Immunotherapeutics
• AZD5305: Astra Zeneca
• Elraglusib (9 ING 41): Actuate Therapeutics
• Pamrevlumab (FG-3019): FibroGen
• NT-I7 (Efineptakin Alfa): NeoImmuneTech
• Olaptesed pegol (NOX-A12): NOXXON Pharma
• siG12D LODER: Silenseed Ltd
• Sotorasib (LUMAKRAS/AMG 510): Amgen
• NGM120: NGM Biopharmaceuticals
• Zenocutuzumab (Zeno, MCLA-128): Merus
• Adagrasib (MRTX849): Mirati Therapeutics
• RX-3117: Rexahn Pharmaceuticals/Ocuphire Pharma/Processa Pharmaceuticals
• Anktiva (N-803): ImmunityBio
• BPM31510 (ubidecarenone): Berg
• SBP-101: Panbela Therapeutics
• Zejula (niraparib): GlaxoSmithKline/Bristol Myers Squibb
• Glufosfamide: Eleison Pharmaceuticals/Molecular Templates
• LOAd703 (delolimogene mupadenorepvec): Lokon Pharma AB
• CAN04 (Nadunolimab): Cantargia AB
• GVAX Pancreatic Tumor Vaccine: Bristol-Myers Squibb, and several others

Pancreatic Cancer Market Dynamics
As the number of instances of pancreatic cancer rises, so does the pancreatic cancer market size, with the advent of genomic profiling technology and selective molecular targeted medicines, biomarkers have become increasingly significant in the clinical management of pancreatic cancer patients. Moreover, survival in pancreatic cancer patients is constantly improving, indicating that a better understanding of tumor pathobiology will lead to better therapies and outcomes in the pancreatic cancer market. Furthermore, due to a dearth of randomized neoadjuvant trials, research into the use of newer and more aggressive systemic regimens in the neoadjuvant setting to treat PDAC could potentially enhance outcomes in the pancreatic cancer market. Agents targeting the four most prevalent mutations in pancreatic cancer, KRAS, TP53, CDKN2A, and SMAD4, are still in clinical trials, and after the launch, they will change the pancreatic cancer market dynamics.

Pancreatic Cancer Market Growth Factors
However, several factors are limiting the growth of the pancreatic cancer market. PDAC is a complicated disease with high intra-tumoral heterogeneity and a thick, desmoplastic stroma that might restrict drug delivery to the tumor. Furthermore, it foreshadows an exceedingly intricate interplay of intercellular signals, making in vitro disease research difficult. Because of the genetic mutation diversity and dense connective tissue that forms the pancreas, PDAC is one of the most chemo-resistant types of cancer.

Scope of the Pancreatic Cancer Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicùm Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others
• Key Pancreatic Cancer Therapies: Motixafortide, Mitazalimab, BPX-601, Tedopi (OSE2101), AZD5305, Elraglusib (9 ING 41), NT-I7 (Efineptakin Alfa), Olaptesed pegol (NOX-A12), siG12D LODER, Sotorasib (LUMAKRAS/AMG 510), NGM120, Zenocutuzumab (Zeno, MCLA-128), Adagrasib (MRTX849), RX-3117, Anktiva (N-803), BPM31510 (ubidecarenone), Zejula (niraparib), Glufosfamide, LOAd703 (delolimogene mupadenorepvec), GVAX Pancreatic Tumor Vaccine, and others
• Therapeutic Assessment: Pancreatic Cancer current marketed and emerging therapies
• Pancreatic Cancer Market Dynamics: Pancreatic Cancer market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Pancreatic Cancer Market Access and Reimbursement

Request Sample Report- https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Key Insights
2. Report Introduction
3. Pancreatic Cancer-Market Overview at a Glance
4. Pancreatic Cancer - Future Prospects
5. Executive Summary of Pancreatic Cancer
6. Key Events
7. Disease Background and Overview
8. Treatment and Management
9. Methodology
10. Epidemiology and Patient Population
13. Emerging Therapies
14. Pancreatic Cancer: Seven Major Market Analysis
15. Market Access and Reimbursement
16. KOL Views
17. SWOT Analysis
18. Unmet Needs
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Do you have any query related to the report? Visit here- https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pancreatic Cancer Market to Progress at a CAGR of 7.3 % by 2032 | DelveInsight here

News-ID: 2720608 • Views:

More Releases from DelveInsight Business Research

Diabetic Kidney Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Medication, Clinical Trials and Companies by DelveInsight | Boehringer Ingelheim, Daiichi Sankyo, ProKidney, Chinook Therapeutics, AbbVie, Inversago Pharma, more
Diabetic Kidney Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevale …
(Albany, USA) DelveInsight's Diabetic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, diabetic kidney disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Diabetic Kidney Disease Market Report • Diabetic Kidney Disease Market is anticipated to
Hypercholesterolaemia Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, and companies by DelveInsight | Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Novo Nordisk, more
Hypercholesterolaemia Clinical Trials 2024: FDA Approvals, Medication, Pipeline …
(Albany, USA) As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 25+ pipeline drugs in the Hypercholesterolaemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Hypercholesterolaemia Pipeline Insight, 2024" report by DelveInsight provides a comprehensive analysis
Motor Neuron Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline, Mechanism of Action, ROA and Companies by DelveInsight | Biohaven Pharmaceuticals, Prilenia Therapeutics, Helixmith, GeneCradle, Zydus Lifescience, more
Motor Neuron Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline, …
(Albany, United States) According to DelveInsight's assessment, the global pipeline for Motor Neuron Disease includes over 180 key companies actively working on the development of more than 200 treatment therapies. DelveInsight's analysis covers clinical trials, therapies, mechanisms of action, routes of administration, and recent developments. "Motor Neuron Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Motor Neuron Disease
Graves Disease Clinical Trials 2024: FDA Approvals, Mediction, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight | TSHR Septerna, EVOQ Therapeutics, Worg Pharmaceuticals, Novartis, Immunovant Sciences, more
Graves Disease Clinical Trials 2024: FDA Approvals, Mediction, Therapies, Treatm …
(Albany, United States) As per DelveInsight's assessment, globally, Graves Disease pipeline constitutes 8+ key companies continuously working towards developing 10+ Graves Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Graves Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graves Disease Market. The Graves Disease Pipeline report embraces in-depth commercial

All 5 Releases


More Releases for Pancreatic

Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of
Pancreatic Cancer Treatment
Pancreatic Cancer Treatment Market describes its growth, size, share, Forecast and trends to 2025 Pancreatic Cancer Treatment Market Production and Demand Analysis 2019 to 2025 Pancreatic Cancer Treatment Market 2019 Manufacturing Analysis and Development Forecast 2025 Pancreatic Cancer Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025 Pancreatic Market to Insight By 2025: Top Key Vendors Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease. Download the sample report at: https://www.pharmaproff.com/request-sample/1024 Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI
Pancreatic Cancer Pipeline Review H1 2019
Pancreatic Cancer - Pipeline Review, H1 2017 Summary Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and
Pancreatic Cancer Drug Pipeline Analysis
“Pancreatic Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each
Exocrine Pancreatic Insufficiency Market 2013
Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023. Browse the full Exocrine Pancreatic Insufficiency Market – (Therapeutic – Pancreatic Enzyme Replacement Therapy (Creon, Zenpep,